asterias.jpg
Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress
August 09, 2018 16:10 ET | Asterias Biotherapeutics
Company Progressing Neurology and Immunotherapy Clinical Programs Anticipates Achievement of Significant Execution Milestones in the Second Half of 2018 and Full Year 2019 to Advance the...
asterias.jpg
Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
July 31, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018
July 26, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
July 17, 2018 07:00 ET | Asterias Biotherapeutics
- Current Readout Includes New Six Month Data for Cohort 5 and Aggregate Trial Data - - Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury...
asterias.jpg
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke
July 12, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
July 11, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
asterias.jpg
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
June 12, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and...
asterias.jpg
Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury
June 05, 2018 07:00 ET | Asterias Biotherapeutics
- AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to...
asterias.jpg
Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
May 16, 2018 07:00 ET | Asterias Biotherapeutics
FREMONT, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological...
asterias.jpg
Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
May 09, 2018 16:12 ET | Asterias Biotherapeutics
-  AST-VAC2 Immunotherapy Program Prepares to Enter Clinic in Second Quarter of 2018 – - Conference Call and Webcast Today, May 9, at 5:00 p.m. ET – FREMONT, Calif., May 09, 2018 (GLOBE NEWSWIRE)...